Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-CAR NK cell therapy
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intraperitoneal
01
Overview
PSMA-CAR NK cell therapy is an investigational "off-the-shelf" immunotherapy that utilizes natural killer (NK) cells engineered with chimeric antigen receptors (CARs). These engineered NK cells are designed to specifically target the prostate-specific membrane antigen (PSMA) protein, which is expressed on prostate cancer cells. The therapy aims to provide a new treatment option for patients with advanced prostate cancer. It is being developed by NantKwest in collaboration with the University of Michigan and Thomas Jefferson University.
02
Targets
FCGR3B (Fc gamma receptor III)Interleukin-15 receptor signaling axis
Beyond the preview
Go deeper on PSMA-CAR NK cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-CAR NK cell therapy.